Big Pharma To Invest More On NCD Partnerships Over Next Decade – IFPMA Report
This article was originally published in PharmAsia News
Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.
You may also be interested in...
MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data
TOKYO - GlaxoSmithKline is making rounds to draw big pharma partners to its patent pool and open laboratory for neglected disease research, but questions linger over what will happen if precompetitive collaboration produces technology or compounds that have use outside of the world's poorest countries
China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.